A previous notice requested comments on the application made for centralized management, but not mass tort designation, of all litigation involving the contraceptive NuvaRing® in a designated North Jersey Mass Tort site. In response to that Notice, and pursuant to Rule 4:38A and Administrative Directive No. 10-07, “Mass Torts – Revised Guidelines and Criteria for Designation,” another application has been made to the Supreme Court, through the Acting Administrative Director of the Courts, for mass tort designation of all NuvaRing® litigation and centralized management of that litigation in one of the designated mass tort sites.
Anyone wishing to comment on or object to this second application regarding NuvaRing® litigation should provide such comments or objections, with relevant supporting documentation, to Glenn A. Grant, J.A.D., Acting Administrative Director of the Courts, P.O. Box 037, Trenton, NJ 08625-0037, by February 15, 2009.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
